Latest Hotspot

The EU approves VANFLYTA®, a new FLT3 inhibitor for FLT3-ITD positive AML patients

17 November 2023
3 min read

The European Union has given the green light for the application of Daiichi Sankyo's VANFLYTA (quizartinib). It is to be used alongside the standard cytarabine and anthracycline induction, as well as the standard cytarabine consolidation chemotherapy. After these therapies, VANFLYTA is to be used individually as a maintenance treatment. This treatment regimen is specifically for adult patients who have been recently diagnosed with acute myeloid leukemia, and whose condition tests positive for FLT3-ITD.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

VANFLYTA, the first FLT3 inhibitor cleared for use in the EU, is designed expressly for treating newly diagnosed FLT3-ITD positive AML patients, accounting for around 25 to 30% of all new AML cases. The European Commission's approval stemmed from the positive reception of the Committee for Medicinal Products for Human Use and is rooted in the findings of the QuANTUM-First study, seen in The Lancet. In this trial, VANFLYTA, supplemented with standard cytarabine and anthracycline induction and standard cytarabine consolidation, and used as ongoing maintenance monotherapy after consolidation, exhibited a 22% drop in the death risk versus just standard chemotherapy in patients with newly diagnosed FLT3-ITD positive AML.

Richard F. Schlenk, MD, Professor and Director of the Trial Center at the National Center of Tumour Diseases, Heidelberg University Hospital and German Cancer Research Center remarked, "This authorization of VANFLYTA is an essential step forward in first-line treating patients suffering from FLT3-ITD positive acute myeloid leukemia, a historically challenging and aggressive subtype to manage."

He further added, "VANFLYTA, a powerful, selective FLT3 inhibitor, significantly boosts total survival when incorporated into standard chemotherapy, and it adds an effective treatment alternative for those newly diagnosed with FLT3-ITD positive AML."

Acute Leukemia Advocates Network's Network Director, Samantha Nier, added, "The favorable decision on VANFLYTA is brilliant news for patients qualified and diagnosed annually with FLT3-ITD positive AML. This difficult leukemia type needs new medication and treatment methods to help patients live longer and we're eagerly awaiting VANFLYTA being accessible in countries across the EU."

"With the clearance for VANFLYTA's use in the European Union, for the first time, patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia can benefit from targeted therapy, specifically evolved and sanctioned for their disease subtype," commented Ken Keller, Global Chief of Oncology Business, as well as President and CEO of Daiichi Sankyo, Inc. "VANFLYTA is the second pioneering drug approved in the EU from our oncology spectrum, emphasizing our dedication to establishing new care standards for cancer patients."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, Word

描述已自动生成

According to the data provided by the Synapse Database, As of November 16, 2023, there are 141 investigational drugs for the FLT3 target, including 139 indications, 221 R&D institutions involved, with related clinical trials reaching 1795, and as many as 16954 patents.

VANFLYTA is approved in the EU in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed AML that is FLT3-ITD positive.

图形用户界面, 文本, 应用程序

描述已自动生成

Tislelizumab: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
5 min read
Tislelizumab: brief review of its R&D progress and the clinical result in 2023 ESMO
17 November 2023
The ESMO Congress presented a summary of the RATIONALE-315 phase III trial: Neoadjuvant tislelizumab plus platinum-based chemotherapy showed a pathological response in operable stage II-IIIA NSCLC, prompting detailed trial result discussions.
Read →
What are CETP inhibitors and how do you quickly get the latest development progress?
What are CETP inhibitors and how do you quickly get the latest development progress?
17 November 2023
CETP inhibitors are drugs designed to increase HDL-C levels which can improve cardiovascular health.
Read →
Orum Therapeutics has revealed that Bristol Myers Squibb has taken over its ORM-6151 program
Latest Hotspot
3 min read
Orum Therapeutics has revealed that Bristol Myers Squibb has taken over its ORM-6151 program
17 November 2023
Orum Therapeutics has announced a final agreement with Bristol Myers Squibb for the acquisition of its ORM-6151 program.
Read →
Tepotinib Hydrochloride Hydrate: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
4 min read
Tepotinib Hydrochloride Hydrate: brief review of its R&D progress and the clinical result in 2023 ESMO
17 November 2023
On 23 Oct 2023, liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib was reported at the ESMO Congress.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.